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Introduction: Although aromatase inhibitors (AIs; for example, letrozole) are highly effective in treating estrogen
receptor positive (ER+) breast cancer, a significant percentage of patients either do not respond to AIs or become
resistant to them. Previous studies suggest that acquired resistance to AIs involves a switch from dependence on
ER signaling to dependence on growth factor-mediated pathways, such as human epidermal growth factor
receptor-2 (HER2). However, the role of HER2, and the identity of other relevant factors that may be used as
biomarkers or therapeutic targets remain unknown. This study investigated the potential role of transcription
factor hypoxia inducible factor 1 (HIF-1) in acquired AI resistance, and its regulation by HER2.
Methods: In vitro studies using AI (letrozole or exemestane)-resistant and AI-sensitive cells were conducted to
investigate the regulation and role of HIF-1 in AI resistance. Western blot and RT-PCR analyses were conducted
to compare protein and mRNA expression, respectively, of ERα, HER2, and HIF-1α (inducible HIF-1 subunit) in
AI-resistant versus AI-sensitive cells. Similar expression analyses were also done, along with chromatin
immunoprecipitation (ChIP), to identify previously known HIF-1 target genes, such as breast cancer resistance
protein (BCRP), that may also play a role in AI resistance. Letrozole-resistant cells were treated with inhibitors to
HER2, kinase pathways, and ERα to elucidate the regulation of HIF-1 and BCRP. Lastly, cells were treated with
inhibitors or inducers of HIF-1α to determine its importance.
Results: Basal HIF-1α protein and BCRP mRNA and protein are higher in AI-resistant and HER2-transfected cells
than in AI-sensitive, HER2- parental cells under nonhypoxic conditions. HIF-1α expression in AI-resistant cells is likely
regulated by HER2 activated-phosphatidylinositide-3-kinase/Akt-protein kinase B/mammalian target of rapamycin
(PI3K/Akt/mTOR) pathway, as its expression was inhibited by HER2 inhibitors and kinase pathway inhibitors.
Inhibition or upregulation of HIF-1α affects breast cancer cell expression of BCRP; AI responsiveness; and
expression of cancer stem cell characteristics, partially through BCRP.
Conclusions: One of the mechanisms of AI resistance may be through regulation of nonhypoxic HIF-1 target genes,
such as BCRP, implicated in chemoresistance. Thus, HIF-1 should be explored further for its potential as a biomarker
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Breast cancer is the most prevalent form of cancer among
women in the United States and second leading cause of
cancer related deaths [1]. Approximately 70% to 80% of
breast cancers express estrogen receptor (ER+) and, con-
sequently, are estrogen-dependent in their growth. Endo-
crine/hormonal therapies have proven effective in treating
ER + breast cancers. Selective estrogen receptor modula-
tors (SERMS), such as tamoxifen, inhibit estrogen action
on breast cancer cells by blocking ER + signaling. Alterna-
tively, aromatase inhibitors (AIs; for example, letrozole,
anastrozole, and exemestane) reduce circulating levels of
estrogen by inhibiting the conversion of androgens to es-
trogen by the enzyme aromatase [2,3]. Comparing the effi-
cacy of tamoxifen versus AIs, a number of clinical studies
have shown that AIs are superior in terms of disease free
survival, time to recurrence and prevention of contralat-
eral breast cancer [4,5]. In the adjuvant setting, AIs are
less toxic with minimal adverse effects compared to
chemotherapy and provide protection against develop-
ment of contralateral breast cancer. AIs are now first-line
treatments for ER + breast cancer in post-menopausal
women [6]. However, a significant percentage (range 30%
to 65%) of patients either does not respond to AIs [7] or
becomes resistant to them [8-10].
Studies from this lab and others suggest that resistance
to AIs occurs after a switch from dependence on ER sig-
naling to dependence on growth factor-mediated path-
ways, such as human epidermal growth factor receptor-2
(HER2), a member of the membrane epidermal growth
factor receptor (EGFR) family of receptor tyrosine ki-
nases, and insulin-like growth factor receptor (IGFR)
[9-11]. Pre-clinical [12] and clinical [10] studies have ex-
plored HER2 inhibitors, trastuzumab and lapatinib, as
treatments for letrozole-resistant breast cancer. Pre-
clinically, our laboratory has shown that trastuzumab
alone or in combination with letrozole decreased HER2
expression, restored ERα expression, and inhibited
tumor growth of MCF-7Ca xenografts that became resist-
ant to letrozole [13]. Clinically, it has been shown that
lapatinib in combination with letrozole significantly in-
creased progression-free survival in patients versus letro-
zole alone as first-line therapy for hormone receptor- and
HER2-positive postmenopausal metastatic breast cancer
[10,14]. However, studies with de novo HER2+ breast can-
cer (that is, not HER2+ breast cancer of acquired AI re-
sistance) indicate that resistance can develop to HER2
inhibitors as well [15,16]. Thus, although it has yet to be
studied, there may be a risk of developing resistance to
second-line HER2 inhibitor therapy in patients who have
already acquired resistance to first-line AI therapy. As a
membrane receptor, HER2 can affect many cellular path-
ways, some of which may not be directly involved in the
development of AI resistance. Targeting another factordownstream of HER2 that more directly mediates effects
specific and essential to the development of AI resistance
may be as effective as targeting HER2 itself, while not hav-
ing the same level of risk of producing second-line ac-
quired resistance. Currently, the mechanism by which
HER2 is involved in AI resistance remains unclear. It is,
therefore, important to: 1) further elucidate the HER2-
mediated pathway that contributes to AI resistance, par-
ticularly characteristics associated with AI resistant breast
cancer cells; and 2) identify other potential factors in-
volved that may serve as novel molecular biomarkers and
therapeutic targets.
One factor that may be involved in HER2-mediated AI
resistance is HIF-1, a heterodimeric transcription factor
made up of an inducible alpha (α) subunit and a consti-
tutively expressed beta (β) subunit [17]. HIF-1α is nor-
mally kept low in cells by proteosomal degradation, but
lack of sufficient oxygen levels (hypoxia, for example, 1%
to 2% O2) prevents this degradation. This leads to in-
creased intracellular HIF-1α protein levels, formation of
HIF-1, and activation of HIF-1 target genes important for
cell survival, metabolic adaptation and angiogenesis. Inter-
estingly, HIF-1 expression and/or activation can also be
regulated by growth factors, hormones and cytokines in-
dependent of O2 levels. For example, ERα- and HIF-1-
mediated signaling pathways are known to interact antag-
onistically [18,19] and cooperatively [20-23]. EGFR and
HER2, as well as kinase signaling pathways, such as the
MAPK and PI3K/Akt pathways, have also been shown to
regulate HIF-1α expression and activity [22,24,25].
The role of hypoxia-regulated HIF-1 in cancer has
been well studied. This is particularly relevant to sizable
tumors whose cancer cells are too distant from existing
blood vessels to get enough oxygen and nutrients [26].
Hypoxia and/or HIF-1 have been implicated in increased
patient mortality and disease progression [27]. Their in-
volvement in tumor formation and metastasis [28,29],
and regulation of cancer stem cells [28,30] and stem cell
markers, such as breast cancer resistant protein (BCRP)
[27,30,31], has also been demonstrated. However, nonhy-
poxic regulation of HIF-1 and its importance in cancer
remains largely unknown. Specific to this study, the
regulation and role of nonhypoxic HIF-1 in breast can-
cer cell resistance to AIs, specifically letrozole, has yet to
be explored. Using a letrozole-resistant cell line devel-
oped from xenograft tumors in our laboratory, this
current study tested the overall hypothesis that nonhy-
poxic HIF-1 is an essential factor in HER2-mediated letro-
zole resistance. More specifically, in letrozole-responsive
tumors, the switch from ERα to HER2-dependent signal-
ing increases HIF-1α expression, independent of nutrient
or oxygen availability. HIF-1 then acts as a key transcrip-
tion factor activating target genes involved in processes
that promote letrozole resistance.




Cell lines (and their ER/HER2 status) used are listed in
Table 1. MCF-7Ca cells obtained from the laboratory of Dr.
Chen through institutional agreement (City of Hope,
Duarte, CA, USA) are MCF-7 cells stably transfected with
the human placental aromatase gene [32,33]. Aromatase is
the enzyme that converts androgens to estrogen. Transfec-
tion of the aromatase gene does not affect ER/HER2 status,
ER activation, or estrogen-dependence of MCF-7 cells, but
it does allow MCF-7 cells to proliferate in response to an-
drogens (for example, androstenedione) and be sensitive to
growth inhibitor effects of aromatase inhibitors [33]. MCF-
7Ca cells were maintained in (D)MEM 1× high glucose
(Invitrogen, Grand Island, NY) supplemented with 5% fetal
bovine serum (FBS), 1% penicillin/streptomycin (P-S), and
700 μg/mL geneticin selective antibiotic (G418). Long-
term letrozole-treated (LTLTCa) cells, developed in our
laboratory [34], are letrozole-resistant breast cancer cells
isolated from MCF-7Ca mouse xenograft tumors treated
for 56 weeks with letrozole and that have become resistant
to the growth inhibitory effects of letrozole. LTLTCa cells
were maintained in phenol red–free (PRF) modified
Improved Minimal Essential Media (IMEM) (Invitrogen,
Grand Island, NY) supplemented with 5% charcoal
dextran-treated FBS (CDT-FBS), 1% P-S, 750 μg/mL G418,
and 1 μM letrozole. LTLTCa cells can be compared to
MCF-7Ca cells in experiments since they originated from
the MCF-7Ca cell population and their expression of ERα
and HER2 returns to levels similar to that of MCF-7Ca cells
after letrozole withdrawal [35]. MCF-7 cells obtained from
American Type Culture Collection (ATCC) were main-
tained in (D)MEM 1× high glucose (Invitrogen, Grand
Island, NY) supplemented with 5% FBS and 1% P-S. Hc7
cells were developed in our laboratory; they are MCF-7
cells transfected with the HER2 gene and overexpress
HER2 [36]. Hc7 cells were maintained in (D)MEM 1× high
glucose (Invitrogen, Grand Island, NY) supplemented with
5% FBS, 1% P-S, and 500 μg/ml hygromycin. AC1 cells areTable 1 ERα and HER2 status and aromatase inhibitor-
sensitivity of cell lines used
Cell line ERα status HER2 status AI-sensitivity
MCF-7Ca + - Yes
LTLT-Ca - + No (to letrozole)
MCF7 + - Yes
MCF7 / HER2 + + ND
AC1 + - Yes
AC1-Ex R + + No (to exemestane)
ERα, estrogen receptor alpha; HER2, human epidermal growth factor
receptor 2; ND: not determined.another set of MCF-7 cells stably transfected with the hu-
man placental aromatase gene [37]. Similar to MCF-7Ca
cells, AC1 cells are ER+/HER2-, proliferate in response to
estrogen or androstenedione, express the aromatase en-
zyme and are sensitive to aromatase inhibitors [38]. AC1
cells, however, were created in our laboratory rather than
Dr. Chen’s, and they express higher levels of aromatase
(data not shown). AC1 cells are maintained in (D)MEM
1x high glucose (Invitrogen, Grand Island, NY) supple-
mented with 5% FBS, 1% P-S, and 800 μg/mL G418.
AC1-exemestane resistant (AC1-ExR) cells, developed
in our laboratory, are exemestane-resistant cells isolated
from AC1 mouse xenograft tumors treated for approxi-
mately 10 weeks with exemestane maintained in PRF
modified IMEM (Invitrogen, Grand Island, NY) supple-
mented with 5% CDT-FBS, 1% P-S, 800 μg/mL G418, and
5 μM exemestane.
For experiments determining the effect of oxygen ten-
sion on protein expression, MCF-7Ca and LTLTCa cells
were plated in passage media and incubated either under
normal (20% O2 at 37°C) or more physiological (5% O2;
using a hypoxia chamber) cell culture conditions for
24 hours. MCF-7 cells used to generate MC-7Ca and
AC1 cells were obtained from the ATCC and, thus, did
not require ethical approval or patient consent.
Reagents
The following drugs were used: letrozole (Novartis,
NY, USA); lapatinib (GlaxoSmithKline Pharmaceutical,
Brentford, Middlesex, United Kingdom); trastuzumab
(Genentech, San Francisco, CA); exemestane (Pfizer, NY,
USA); cycloheximide (#C1988), actinomycin D (#A9415),
and cobalt chloride (CoCl2; #C8661) (all from Sigma, St.
Louis, MO). The following antibodies were used in
western blot analyses: HER2 (#04-1127) and BCRP
(EMD Millipore, Billerica, MA); HIF-1α (#610959; BD
Biosciences); ERα (#8644; Cell Signaling Technology,
Danvers, MA); phosphorylated and total ERK1/2, Akt
(#4058 and #4685), mTOR (#2971 and #2972) and p70 S6
kinase (#9205 and #9202) all from Cell signaling Technology,
Danvers, MA); and β-actin (#4970; Cell Signaling Technology,
Danvers, MA).
Western blot analysis
Plated cells were washed with ice-cold PBS and then lysed
with radioimmunoprecipitation (RIPA) buffer containing
protease (#11836145001) and phosphatase inhibitors
(#4906837001) (both from Roche Applied Sciences, Indiana-
polis, IN) by sonication and incubation for 20 minutes at
4°C. Lysed samples were centrifuged at 14,000 rpm for
20 minutes at 4°C to collect protein lysates (supernatant). A
total of 10 to 40 μg of protein underwent 10% SDS–poly-
acrylamide gel electrophoresis (SDS-PAGE) and was trans-
ferred to a polyvinylidene difluoride membrane (PVDF;
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were probed with specific mouse or rabbit primary anti-
bodies and either goat anti-mouse or –rabbit secondary
antibodies conjugated to horseradish peroxidase (#17 2–
1011 and#172-1019; Biorad, Hercules, CA), respectively.
Blots were developed using SuperSignal West Pico Chemi-
luminescent Substrate (#34080; Thermo Scientific,
Waltham, MA). Blots that were to be re-probed were
stripped with Restore Western Blot Stripping Buffer
(#21059; Thermo Scientific, Waltham, MA) for 40 minutes
at room temperature prior to incubation with another pri-
mary antibody. Densitometry was performed on each blot
using either ImageQuant or ImageJ.
Reverse transcripase-polymerase chain rection
RNA extraction and reverse transcription (RT)
RNA was extracted and purified using the RNeasy Mini
Kit (#74104; Qiagen, Valencia, CA). RNA was reverse
transcribed to complementary DNA (cDNA) using 200U
of Moloney murine leukemia virus reverse transcriptase
(#28025013; Invitrogen, Grand Island, NY) and incubat-
ing at 37°C for one hour.
Real-time PCR
mRNA expression analyses were carried out by real-time
PCR using a DNA Opticon system (MJ Research,
Waltham, MA) and using DyNAmo SYBR green qPCR
mix (New England Biolabs, Ipswich, MA). Standard
curves were generated by serially diluting the sample ex-
pected to have the most amount of the PCR product.
The yield of product for each unknown sample was cal-
culated by applying its threshold cycle, or C(T), value to
the standard curve using the Opticon Monitor analysis
software (version 1.01, MJ Research, Waltham, MA).
Values were normalized to corresponding 18S rRNA
values and expressed as the fold increase relative to con-
trols. Primers for HER2, HIF-1α, BCRP, GAPDH, BMI-1,
Nanog and TWIST were obtained from (Sigma, St. Louis,
MO or Qiagen Valencia, CA).
Chromatin immunoprecipitation assay
For the in vitro chromatin immunoprecipitation
(ChIP) assay, the treated cells were washed with
DPBS and fixed with 1% formaldehyde/dulbecco's
phosphate buffered saline (DPBS) for 10 minutes at
37°C, after which the cells were washed with ice-cold
DPBS containing protease inhibitors. The cells were
collected into 1 mL DPBS and pelleted by centrifuga-
tion at 6,000 rpm for five minutes at 4°C. The cell
pellet was resuspended in nuclear lysis buffer (ChIP
kit, #17–295 Millipore, Billerica, MA) and incubated
on ice for 15 minutes. Samples were sonicated on ice
for 7 × 10-second cycles, with 20-second pauses be-
tween each cycle. The sonicated samples werecentrifuged at 14,000 rpm for 10 minutes at 4°C. The
sonicated samples were diluted 1:10 with dilution buf-
fer (ChIP kit) before being immunocleared in a solu-
tion containing protein A- or G-Sepharose slurry
(#16-156 and #16-266, respectively; Millipore, Billerica,
MA) in Tris/ethylenediaminetetraacetic acid (EDTA) buffer,
salmon sperm DNA (#15632011; Invitrogen, Grand
Island, NY), and normal mouse or rabbit serum (#M5905
and #R9133; Sigma, St. Louis, MO) for two hours at 4°C.
Immunocleared supernatants were incubated overnight at
4°C with anti-HIF-1α antibody (#610959; BD Biosciences).
Protein A- or G-Sepharose beads and salmon sperm DNA
were then added and incubated for one hour at 4°C.
The beads were then washed sequentially with 1 mL
each of wash buffers (ChIP kit). The protein-DNA
complexes were eluted by twice incubating the beads
in an elution buffer for 10 minutes at room
temperature with vigorous mixing. To separate immu-
noprecipitated protein and DNA, the pooled elutes
were incubated at 65°C overnight. The DNA was
purified using the QIAquick PCR Purification kit
(#28106; Qiagen Valencia, CA). The yield of target
region DNA in each sample after ChIP was analyzed
by real-time PCR using primers for a region of
BCRP promoter that contains a HIF-1 response
element (Invitrogen, Grand Island, NY) or a negative
control open reading frame (ORF)-free intergenic re-
gion (ChIP-qPCR Human IGX1A Negative Control
primers (#GPH100001C(−)01A, Qiagen, Valencia,
CA).
Mammosphere assay
The mammosphere assay was performed using re-
agents from Stem Cell Technologies (Vancouver, CA),
according to the manufacturer’s instructions. Single
cells were suspended in complete Mammocult media
according to the manufacturer’s instructions (#05620)
and plated in ultra low attachment plates (#CLS3471;
Corning, Tewksbury, MA) at a density of 10,000 to
20,000 cells/mL. Media were replenished every three
days. Mammospheres were counted after at least
seven days and up to three to four weeks. Spheres
with a colony count of at least 50 cells were consid-
ered mammospheres.
Statistical analysis
All experiments were performed two to three times,
with multiple replicates at each time point (total of n
= 4 to 6 independent samples). Thus, quantified
values are means of n = 4 to 6 independent samples/
group with standard deviations (SD). Statistical ana-
lyses were performed using Graph Pad Prism software
and included: 1) a two-sided t-test to compare two
groups (for example, MCF-7Ca versus LTLTCa); 2) a
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adjustment to compare three or more groups (for ex-
ample, different treatment types, time points, and so
on); and 3) a two-way ANOVA with Bonferroni ad-
justment (for example, different cell types and treat-
ments or genes). For mRNA stability, the linear
mixed-effects models approach was used. To assure
approximate normality, the logarithmic transformation
was applied to the normalized value of mRNA, that
is, for each cell line, mRNA expression at each acti-
nomycin D time point was normalized using the cor-
responding vehicle-treated samples. Average mRNA
expressions were estimated and compared at the pre-
specified time-points (Additional file 1: Table S1.1
and Table S1.2), the trends over time were deter-
mined for HIF-α mRNA and BCRP mRNA. All re-
quired models’ diagnostics were performed. There
were fixed effects for time, experiment, cell lines and
interactions between time and cell lines. The models
had hierarchical structure as repeated measurements
were taken within a well, nested within time, cell line,
and experiment. The compound symmetry was
chosen as appropriate to model the variance structure
of the random effects. Statistical tests were two-sided.
Analyses were conducted using SAS (v.9.22, SAS Inc.,
NC, USA). The alpha level applied in all statistical
analyses was P <0.05.Figure 1 Comparison of protein expression in parental MCF-7Ca and
A) Parental MCF-7Ca and LTLTCa cells were plated and cultured in their res
physiological conditions) or 20% O2 (normal, nonhypoxic cell culture condi
were analyzed by Western blot analysis. Shown are representative blots an
Densitometry results are expressed as mean fold-change in protein levels c
(mean ± SD of n = 6 independent cell samples/group; *versus MCF-7Ca and
P = .5749, interaction between cell type and % O2 P = .7337; ERα effect of c
type and% O2 P = .2016; HIF-1α effect of cell type P = 0.0024, effect of % O2
ANOVA). B) LTLTCa and parental MCF-7Ca cells were plated and cultured in t
extracted when 2X density plates reached approximately 90% to 95% conflue
50% to 60% confluency. HIF-1α and β-actin protein were analyzed by Western
to MCF-7Ca cells after normalization to β-actin. (mean ± SD, n = 6 independen
type P < 0.0001, interaction between cell confluency and cell type P = 0.0006,
alpha; HER2, human epidermal growth factor receptor 2; HIF-1α, hypoxia induciResults
LTLTCa cells have higher HIF-1α protein expression than
MCF-7Ca cells under nonhypoxic conditions
Previous studies have shown that a decrease in ERα and
an increase in HER2 protein expression is associated
with acquired AI-resistance [9-11], represented in this
current study by LTLTCa cells. To determine whether
HIF-1 expression is also associated with acquired AI-
resistance, protein expression of the inducible HIF-1α
subunit in LTLTCa and MCF-7Ca cells was determined.
As expected, LTLTCa cells had 0.3 ± 0.02-fold ERα
(P <0.0001); and 18.0 ± 5.5-fold HER2 (P = 0.002) protein
levels compared to letrozole-sensitive parental MCF-7Ca
cells under normal cell culture conditions (that is, non-
hypoxic; 20% O2) (Figure 1A). LTLTCa cells also had
15.7 ± 5.9–fold (versus 1.0 ± 1.4 MCF-7Ca at 20% O2)
higher basal levels of HIF-1α protein than their parental
MCF-7Ca cells, which expressed little to no HIF-1α
(Figure 1A).
Since oxygen levels in normal tissue [39,40], including
the breast [26,41], range from 2% to 5%, and HIF-1α
protein is known to be sensitive to O2 levels [17], pro-
tein expression at 5% O2 was also determined
(Figure 1A). ERα and HER2 levels in both LTLTCa and
MCF-7Ca cells remained unchanged when the percent
O2 was reduced to more physiological levels. HIF-1α ex-
pression, in contrast and as expected, increased in bothLTLTCa cells under different oxygen tension and cell confluency.
pective passage media under either 5% O2 (in vivo normoxic/
tions). Total protein was extracted and HER2, ERα, HIF-1α and β-actin
d overall densitometry results of n = 6 independent cell samples/group.
ompared to MCF-7Ca cells in 20% O2 after normalization to β-actin
† versus 20% O2; HER2 effect of cell type P = 0.0002, effect of % O2
ell type P <0.0001, effect of % O2 P = .2879, interaction between cell
P = 0.0087, interaction between cell type and% O2 P = 0.0413; two-way
heir respective passage media at 1X or 2X density. Total protein was
ncy, and, consequently, 1X density plates reached approximately
blot. Densitometry results are expressed as mean fold-change compared
t cell samples/group; effect of cell confluency P = 0.0006, effect of cell
two-way ANOVA). ANOVA, analysis of variance; ERα, estrogen receptor
ble factor 1 α subunit; n, number; SD, standard deviation.
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2.2-fold versus MCF-7Ca at 20% O2, Figure 1A). Never-
theless the fold differences in HIF-1α expression be-
tween LTLTCa cells and MCF-7Ca persisted and were
significant.
Lastly, since HIF-1α protein expression can also be
affected by cell density/confluency [42,43], protein
expression in LTLTCa and MCF-7Ca cells at both
approximately 50% and 95% confluencies were also
analyzed. LTLTCa cells had higher levels of HIF-1α
protein than MCF-7Ca cells under nonhypoxic con-
ditions at both cell densities (P <0.0001, Figure 1B).
Furthermore, while MCF-7Ca cells still had little or
no HIF-1α protein at 95% confluency, LTLTCa cells ex-
hibited a significant increase in HIF-1α (P = 0.0006;
Figure 1B). These results suggest that: 1) letrozole-
resistant LTLTCa cells basally and inherently have higher
HIF-1α protein expression than letrozole-sensitive MCF-
7Ca cells regardless of O2 levels or cell density; and 2)Figure 2 Comparison of HIF-1α mRNA expression and stability in LTL
and cultured in their respective passage media under normal cell culture (n
and 18S rRNA were analyzed by real-time RT-PCR analysis. Results shown a
MCF-7Ca cells after normalization to 18S rRNA (mean ± SD of n = 6 indepen
P <0.0001, effect of cell type P = 0.1376, interaction between gene type and
P <0.0001; two-way ANOVA). B) LTLTCa and MCF-7Ca cells were treated wi
extracted and HIF-1α mRNA underwent real-time RT-PCR. Results are expre
expression at various timepoints (trend over time) after normalization to co
model, adjusting for experiment, cell line and cell line*time interaction (me
cell line, time, their interaction and experiment). C) LTLTCa cells were treate
cycloheximide for 0 to 60 minutes. Whole cell protein was extracted and u
representative blots and overall densitometry results of n = 6 independent
fold-change in protein levels compared to vehicle-treated-0 minutes cyclohex
cell samples/group; *versus no CoCl2-0 minutes CHX, P <0.0001, one-way ANO
human epidermal growth factor receptor 2; HIF-1α, hypoxia inducible factor 1LTLTCa cells are more sensitive to inducers of HIF-1α ex-
pression, such as decreased O2 levels and cell density/
confluency.
HIF-1α expression in LTLTCa cells is due to increased
protein synthesis
Elevated HIF-1α protein expression in cells can result
from increased protein stability and/or synthesis [44].
In LTLTCa cells, higher levels of HIF-1α may be due
to increased protein synthesis (for example, increased
mRNA translation to protein) for several reasons.
First, unlike HER2 and ERα mRNA, HIF-1α mRNA
expression was not significantly different between
LTLTCa cells and MCF-7Ca cells (Figure 2A). This
rules out increased HIF-1α gene transcription as the
basis for increased HIF-1α protein. Second, overall
through 16 hours of actinomycin D treatment HIF-1α
mRNA was not more stable in LTLTCa cells com-
pared to MCF-7Ca cells (Figure 2B and AdditionalTCa and MCF-7Ca cells. A) LTLTCa and MCF-7Ca cells were plated
onhypoxic) conditions. Total RNA was extracted and HER2, ERα, HIF-1α
re expressed as the mean fold-change in mRNA levels compared with
dent cell samples/group; *versus MCF-7Ca; effect of gene type
cell type P <0.0001; *MCF-7Ca versus LTLTCa for specific gene,
th vehicle or 0.5 μg/ml actinomycin D for 0 to 16 hours. Total RNA was
ssed as least square means of log transformed averages of mRNA
rresponding vehicle-treated samples and analysis by linear mixed effect
ans ± SD of n = 6 independent samples/group; P <0.001 for effect of
d with vehicle or 100 μM CoCl2 for three hours and then with 100 uM
nderwent Western blot for HIF-1α and AIB1 protein. Shown are
cell samples/group. Densitometry results are expressed as mean
imide cells after normalization to AIB1 (mean ± SD of n = 6 independent
VA). ANOVA, analysis of variance; ERα, estrogen receptor alpha; HER2,
α subunit; n, number; SD, standard deviation.
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in LTLTCa cells than MCF-7Ca cells prior to four
hours of actinomycin D treatment, but it was less by
sixteen hours (Figure 2B). Statistical analysis of HIF-
1α mRNA expression over time in LTLTCa cells com-
pared to MCF-7Ca cells showed significant effects of
time, and cell line, and their interaction (P <0.001;
linear mixed effect model of time regression analysis).
Third, investigation of HIF-1α protein stability after
treatment with the protein synthesis inhibitor cyclo-
heximide with or without the HIF-1α protein
stabilizer CoCl2 [45], demonstrated that after addition
of the protein synthesis inhibitor cycloheximide, HIF-
1α protein in vehicle-treated LTLTCa cells rapidly de-
graded within 15 minutes (Figure 1C). In contrast,
HIF-1α expression in CoCl2-treated LTLTCa cells was
elevated by 2.8 ± 0.0-fold compared to 1.0 ± 0.3-fold in
vehicle-treated cells (P <0.0001), and did not decrease
through 60 minutes of cycloheximide treatment (2- to
2.8-fold at each time point, P <0.001) (Figure 1C).
These protein results are consistent with what is known
about the rapid proteosomal degradation of HIF-1α
protein in nonhypoxic cells [44], and the effect ofFigure 3 Regulation of HIF-1α protein in LTLTCa cells. A) LTLTCa cells
inhibitor U0126, 20 μM LY294002 PI3K pathway inhibitor, 500 μg/ml trastuzum
(P = 0.128), phospho- and total-ERK1/2 (P <0.0001 for p-ERK), phospho- and to
phospho- and total p70 S6 kinase (P <0.0001), ERα (P <0.0001), HIF-1α (P = 0.00
blots and overall densitometry results of n = 6 independent cell samples/
protein levels compared to vehicle-treated cells after normalization to β-a
hicle, P <0.05; † versus vehicle, P <0.001, one-way ANOVA). ANOVA, analy
growth factor receptor 2; HIF-1α, hypoxia inducible factor 1 α subunit; n,
rapamycin.CoCl2 on HIF-1α protein stability [46]. These protein
stability results further rule out increased protein sta-
bility as the basis for elevated HIF-1α levels in LTLTCa
cells under nonhypoxic conditions.
HER2-activated PI3K/Akt/mTOR pathway regulates HIF-1α
expression in LTLTCa cells
Since LTLTCa cells have significantly higher HER2 protein
and mRNA expression compared to MCF-7Ca cells ([47],
Figures 1A and 2A), this current study sought to deter-
mine whether endogenously overexpressed HER2 affects
HIF-1α in LTLTCa cells. To do this, the effects of
two types of HER2 inhibitors on HIF-1α were studied
(Figure 3). Lapatinib is a HER2 kinase inhibitor that
does not affect HER2 expression but does decrease HER2
activation of downstream kinase pathways (for example,
MAPK, PI3K/Akt/mTOR pathway). Trastuzumab is a
HER2 monoclonal antibody that decreases HER2 expres-
sion and its activation of downstream kinase path-
ways. As expected, only trastuzumab significantly reduced
HER2 protein expression (0.4 ± 0.05 versus 1 ± 0.2 vehicle-
treated), but both lapatinib and trastuzumab inhibited
activation of the MAPK (0.2 ± 0.1-fold and 0.3 ± 0.01-fold,were treated with either vehicle, 1 μM lapatinib, 20 μM MAPK pathway
ab or 100 nM RAD001 for 24 hours. Total protein was extracted and HER2
tal-Akt (P <0.0001 for p-Akt), phospho- and total mTOR (P = 0.0071),
03), and β-actin were analyzed by Western blot. Shown are representative
group. Densitometry results are expressed as mean fold-change in
ctin (mean ± SD, n = 6 independent cell samples/group; *versus ve-
sis of variance; ERα, estrogen receptor alpha; HER2, human epidermal
number; SD, standard deviation; mTOR, mammalian target of
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2, P <0.05) and PI3K/Akt pathways (0.2 ± 0.2-fold
and 0.3 ± 0.08-fold versus 1 ± 0.09-fold vehicle of p-Akt,
P <0.01) (Figure 3). Both inhibitors also significantly
decreased HIF-1α protein expression in LTLTCa cells
(0.2 ± 0.2-fold and 0.4 ± 0.2-fold, respectively, versus
of 1 ± 0.1-fold vehicle-treated, P <0.001) (Figure 3).
Since both the MAPK and PI3K/Akt/mTOR path-
ways are activated by HER2 and known to regulate
HIF-1α expression and activity [44,48,49], the effect
of specific inhibition of each pathway on HIF-1α ex-
pression was also studied (Figure 3). As expected,
the MAPK inhibitor U0126 effectively decreased
p-ERK1/2 protein expression (0.01 ± 0.01-fold versus
1 ± 0.2-fold vehicle-treated, P <0.001), and the PI3K
inhibitor LY294002 decreased p-Akt (0.01 ± 0.01-fold
versus 1 ± 0.09-fold vehicle-treated), downstream Akt
target p-mTOR (0.5 ± 0.2-fold versus 1 ± 0.2-fold
vehicle-treated), downstream mTOR target p-70 S6
kinase (0.02 ± 0.02-fold versus 1 ± 0.1-fold vehicle-
treated). Also as expected, the mTOR inhibitorFigure 4 Comparison of BCRP protein and mRNA expression and stab
cells were plated and cultured in their respective passage media under norm
BCRP and β-actin were analyzed by Western blot analysis. Densitometry resul
cells after normalization to β-actin (mean ± SD, n = 6 independent cell sample
extracted and BCRP mRNA, VEGF mRNA and 18S rRNA were analyzed by real-
levels compared with MCF-7Ca cells after normalization to 18S rRNA (mean ±
two-tailed t-test). C) LTLTCa and MCF-7Ca cells were treated with vehicle or 0
BCRP mRNA was analyzed by real-time RT-PCR. Results are expressed as least
timepoints (trend over time) after normalization to corresponding vehicle-trea
experiment, cell line, and cell line*time interaction (mean ± SD of n = 6 indep
P = 0.0025, effect of cell type P = .3749, interaction between gene type and ce
BCRP, breast cancer resistant protein; n, number; SD, standard deviation; VEGFRad001 decreased phosphorylation of mTOR (0 ±
0.01 versus 1 ± 0.1-fold vehicle) and p70 S6 kinase
(0.02 ± 0.02-fold versus 0.1 ± 0.1-fold vehicle) without
affecting upstream Akt (Figure 3). HIF-1α protein
expression was significantly decreased in LTLTCa
cells with LY294002 (0.1 ± 0.1-fold versus 1 ± 0.1-fold
vehicle-treated) and Rad001 (0.1 ± 0.06-fold versus 1
± 0.1-fold vehicle-treated), but not by U0126. Over-
all, these results indicate that HER2 activation of
the PI3K/Akt/mTOR pathway induces HIF-1α
expression. They also suggest that the HER2-
activated MAPK pathway in LTLTCa cells has dis-
tinct functions from that of the PI3K/Akt/mTOR
pathway.
HIF-1α involvement in HER2 regulation of BCRP
expression
As a transcription factor, HIF-1 may be mediating the ef-
fects of HER2 on target genes that contribute to the
LTLTCa cell phenotype. One such gene may be the
breast cancer resistance protein (BCRP), an effluxility in LTLTCa and MCF-7Ca cells. LTLTCa and parental MCF-7Ca
al cell culture (nonhypoxic) conditions. A) Total protein was extracted and
ts are expressed as fold-change in protein levels compared to MCF-7Ca
s/group; *versus MCF-7Ca, P <0.0001, two-sided t test). B) Total RNA was
time RT-PCR analysis. Results are expressed as the fold-change in mRNA
SD, n = 6 independent cell samples/group; *versus MCF-7Ca, P <0.0001,
.5 μg/ml actinomycin D for 0 to 16 hours. Total RNA was extracted and
square means of log transformed averages of mRNA expression at various
ted samples, and analysis by linear mixed effect model adjusting for
endent cell samples/group; *versus MCF-7Ca; effect of gene type
ll type P = 0.0025; two-way ANOVA). ANOVA, analysis of variance;
, vascular endothelial growth factor.
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http://breast-cancer-research.com/content/16/1/R15transporter protein and stem cell marker implicated in
cancer cell chemoresistance [50,51]. BCRP is also known
to be a HIF-1 target gene [31]. Recently, findings from
our laboratory have shown that BCRP protein is overex-
pressed in LTLTCa cells compared to MCF-7Ca cells
and that BCRP is important in stem cell characteristics
of LTLTCa (for example, mammosphere formation, side
population percentage) [52]. This current study con-
firms the overexpression of BCRP protein in LTLTCa
cells, and further demonstrates that BCRP mRNA ex-
pression (3 ± 0.6-fold versus 1 ± 0.2-fold vehicle-treated,
P <0.0001, one-way ANOVA) is also elevated compared
to MCF-7Ca cells (Figure 4A-B). BCRP mRNA stability
was also compared between the two cell types. Consist-
ent with findings of others in MCF-7 cells [53], BCRP
mRNA is fairly stable through 16 hours of actinomycin D
treatment in MCF-7Ca cells (Figure 2C). Overall, BCRPFigure 5 Effect of lapatinib and CoCl2 on BCRP protein and mRNA ex
A) LTLTCa cells were treated with 1 μM lapatinib for 0 to 48 hours. Total pr
p-ERK1/2, and ERK. Shown are representative blots and overall densitometr
are expressed as mean fold-change compared to 0 hours after normalizatio
0 hours lapatinib; P = 0.0004 for ERK for HIF-1α, P = 0.0017 for BCRP, P = 0.00
RNA was extracted and underwent real-time RT-PCR for BCRP mRNA and 1
compared with vehicle after normalization to 18S rRNA (mean ± SD of n =
lapatinib, U0126 or LY294002, P <0.01; overall P <0.0001, one-way ANOVA).
CoCl2 for 24 hours. Protein-DNA complexes from LTLTCa cells were analyze
antibody or an equivalent volume of normal mouse serum (negative contr
promoter, which contains the HRE to which HIF-1 binds, or ORF-free intergen
Results are the mean fold increase compared with vehicle-treated cells after n
cells sample/group; *versus vehicle-HIF-1 IP; P = 0.004 for BCRP promoter, P =
ANOVA, analysis of variance; BCRP, breast cancer resistant protein; ChIP, chrom
n, number; SD, standard deviation.mRNA in LTLTCa cells was not significantly more stable
than in MCF-7Ca (Figure 4C). Statistical analysis of BCRP
mRNA expression over time in LTLTCa cells compared to
MCF-7Ca cells showed significant effects of time, but
not cell line (effect of time P < 0.001; effect of cell line
at P = 0.049; linear mixed effect model of time regression
analysis). Thus, overexpression of BCRP in LTLTCa cells
is attributed to increased synthesis at the gene transcrip-
tion level.
In order to elucidate the factors and pathways involved
in regulating BCRP expression, the effects of the HER2
kinase inhibitor lapatinib, HIF-1α stabilizer CoCl2, and/or
specific kinase pathway inhibitors U0126 (MAPK path-
way) and LY294002 (PI3K/Akt pathway) on BCRP protein
or mRNA expression were assessed (Figure 5A-B). Lapati-
nib reduced both BCRP protein (0.2-fold versus 1.0-fold
vehicle, P <0.01) and mRNA (0.6 ± 0.2-fold versus 1.0pression and on HIF-1α binding to the BCRP promoter. A-B),
otein was extracted and underwent Western blot for HIF-1α, BCRP,
y results of n = 6 independent cell samples/group. Densitometry results
n to ERK (mean ± SD of n = 6 independent cell samples/group; *versus
09 for phospho-ERK1/2, P = 1 for ERK-1/2; one-way ANOVA). B) Total
8S rRNA. Real-time results are the mean fold-change in mRNA levels
6 independent cell samples/group; *versus vehicle, P <0.05; † versus
C) LTLTCa were treated with vehicle, 1 μM lapatinib, and/or 100 μM
d by ChIP analysis. Immunoprecipitation was done either with HIF-1α
ol). Primers for either the −290 to −101 region of the human BCRP
ic region (negative control DNA region) were used for real-time PCR.
ormalization to input samples of each (means ± SD, n = 6 independent
.2972 for negative control ORF-free intergenic region; one-way ANOVA).
atin immunoprecipitation; HIF-1α, hypoxia inducible factor 1 α subunit;
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levels in LTLTCa cells. This decrease correlated with
lapatinib’s inhibitory effects on HIF-1α and p-ERK1/2
expression. Inhibition of either the MAPK or PI3K/Akt
pathways also resulted in decreased BCRP mRNA levels
(0.7 ± 0.05-fold and 0.55 ± 0.08-fold versus 1.0 ± .0.02
vehicle-treated, P <0.01, respectively; Figure 5B). CoCl2
treatment conversely increased BCRP mRNA in LTLTCa
cells. Co-treatment with lapatinib and CoCl2 resulted in
BCRP mRNA levels that tended to be intermediate of
lapatinib-inhibited and CoCl2-induced levels, but not
significantly different from either one and from vehicle
(Figure 5B).
Although results in Figure 5A-B suggested that HER2,
via the MAPK and PI3K/Akt pathways, and HIF-1α are
both involved in regulating BCRP expression in LTLTCa
cells, these expression analyses did not test whether HIF-
1α actually mediates the effects of HER2 on target genes.
ChIP analysis was, therefore, performed to determine
HIF-1α binding to the BCRP promoter under basal, non-
hypoxic conditions and after lapatinib or CoCl2 treatment.Figure 6 Effect of YC-1 on HIF-1α and BCRP expression and cell viability
24 hours and effects on HIF-1α (A) and BCRP (B) expression and cell viability (
was extracted and HIF-1α and β-actin were analyzed by Western blot analysis
independent cell samples/group. Densitometry results are expressed as mean
β-actin (mean ± SD of n = 6 independent cell samples/group; *versus 0 hours
YC-1 treatment, total RNA was extracted and BCRP mRNA and 18S rRNA were
the mean fold-change in mRNA levels compared with vehicle after normaliza
*versus 0 hours YC-1, P <0.001; overall P <0.0001, one-way ANOVA). C) Viabilit
YC-1. Results are expressed as mean percent of 0 hours average (mean ± SD,
P <0.0001, one-way ANOVA). ANOVA, analysis of variance; BCRP, breast cancer
3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide; n, number; SD, sReal-time PCR analysis of immunoprecipitated DNA after
ChIP showed that under basal, nonhypoxic conditions
HIF-1α was bound to a hypoxia-response element (HRE)-
containing region of the BCRP promoter in LTLTCa cells
(Figure 5C). CoCl2 significantly increased HIF-1α binding
to the BCRP promoter, but lapatinib treatment prevented
this binding (versus 1 ± 1.2-fold vehicle-treated, P = 0.004,
one-way ANOVA). Specificity of immunoprecipitation was
confirmed by the lack of immunoprecipitated DNA in
the negative IP control samples, as well as on the nega-
tive control DNA (P = 0.2972, one-way ANOVA). In
addition, samples in the BCRP promoter PCR (exclud-
ing input) amplified at cycles 20 to 30, while samples in
the negative control DNA region PCR (excluding input)
amplified at cycles 32 to 40. Correlation between HIF-1α
binding to the BCRP promoter and changes in BCRP
mRNA and protein expression in the absence or presence
of lapatinib suggests that HER2-regulated HIF-1 is in-
volved in BCRP gene expression in LTLTCa cells.
Such regulation, however, does not appear to be relevant
to all known HIF-1 target genes. Vascular endothelialin LTLTCa cells. LTLTCa cells were treated with 100 μM YC-1 for 0 to
C) were determined. A) After 0 to 4 hours of YC-1 treatment, total protein
. Shown are representative blots and overall densitometry results of n = 6
fold-change in protein levels compared to 0 hours after normalization to
YC-1, P <0.001; overall P <0.0001, one-way ANOVA). B) After 0 to 8 hours
analyzed by real-time RT-PCR analysis. Real-time results are expressed as
tion to 18S rRNA (mean ± SD, n = 6 independent cell samples/group;
y of cells was measured by MTT assay after 0 to 24 hours treatment with
n = 4 independent cell samples/group; *versus 0 hours, P <0.001; overall
resistant protein; HIF-1α, hypoxia inducible factor 1 α subunit; MTT,
tandard deviation.
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http://breast-cancer-research.com/content/16/1/R15growth factor (VEGF), another known HIF-1 target gene
and important therapeutic target in cancer [17], is not
upregulated in LTLTCa cells compared to MCF-7Ca cells
(Figure 2B). Also, despite being induced by CoCl2, VEGF
mRNA expression was not sensitive to lapatinib (data not
shown).Effect of specific inhibition of HIF-1α on BCRP
To further support a connection between HIF-1α and
BCRP, HIF-1α expression in LTLTCa cells was specific-
ally inhibited by either YC-1, a known pharmacological
inhibitor of HIF-1α [54,55] or siRNA. Similar to obser-
vations with lapatinib treatment, HIF-1α protein and
BCRP mRNA expression were significantly decreased
(0.1 ± 0.1-fold versus 0.1 ± 0.3-fold vehicle-treated and
0.5 ± 0.05-fold versus 1 ± 0.15-fold vehicle treated P
<0.0001, respectively) in LTLTCa cells within eight hours
of YC-1 treatment (Figure 6A-B). This correlated with a
30% to 40% decrease in LTLTCa cell viability by 16 and
24 hours, respectively (Figure 6C). Specific inhibition of
HIF-1α expression by siRNAs also significantly de-
creased both HIF-1α mRNA (approximately 0.4 ± 0.04-
fold versus 1 ± 0.2-fold negative control siRNA, P =
0.0057, one-way ANOVA) and protein (0.3 ± 0.1-fold to
0.03 ± 0.1-fold versus 1 ± 0.05-fold negative control, P
<0.0001, one-way ANOVA), as well as BCRP mRNA (0.4-
to 0.6-fold versus 1 ± 0.2-fold negative control siRNA, P
<0.0001, one-way ANOVA) expression after 48 hours
(Figure 7A-B).Figure 7 Effect of HIF-1α siRNA on mRNA expression in LTLTCa cells.
two siRNAs for HIF-1α for 48 hours. Total mRNA was extracted and HIF-1α
Real-time results are expressed as the mean fold-change in mRNA levels co
± SD, n = 6 independent samples/group; *versus negative control, P = 0.005
were plated in passage media and then treated with two siRNAs for HIF-1α
protein were analyzed by Western blot. Shown are representative blots and
Densitometry results are expressed as mean fold-change in protein levels com
n = 6 independent cell samples/group; *versus negative control (NC), P <0.00
resistant protein; HIF-1α, hypoxia inducible factor 1 α subunit; n, number; SD,Correlation between HER2, HIF-1α, and BCRP in HER2-
transfected cells and another AI-resistant cell line
To further confirm the role of HER2 in regulating HIF-
1α and BCRP and to determine if ERα is also involved,
protein expression in Hc7 cells, ERα +MCF-7 cells
transfected with HER2 gene was also studied. Similar to
ERα-/HER2+ LTLTCa cells, Hc7 cells overexpressed
phospho-ERK, HIF-1α and BCRP protein expression
compared to ERα+/HER2-parental MCF-7 cells
(Figure 8A). Furthermore, HER2 inhibition by lapatinib de-
creased HIF-1α protein levels in Hc7 cells (0.1 ± 0.1-fold
versus vehicle, P <0.0001; Figure 8B). Interestingly, inhib-
ition of ERα alone by the ERα antagonist ICI 182,780 also
reduced HIF-1α levels, but its effect on the protein level
was significantly less than that of lapatinib alone or lapati-
nib and ICI182,780 in combination (Figure 8C). Another
AI-resistant cell line, exemestane-resistant AC1-ExR
breast cancer cells, was also analyzed. Despite retaining
ERα, AC1-ExR cells also showed higher HER2, HIF-1α
and BCRP protein levels. Overall, these results further in-
dicate that increased HER2 and HER2-activated kinase
pathways correlate with increased HIF-1α. They also indi-
cate that while ERα can play a role in regulating HIF-1, as
has been suggested by other studies [22], HER2 is likely to
be the more important factor in the cells studied.
Functional importance of HIF-1α in LTLTCa cells
Effect of HIF-1α inhibition on LTLTCa cells
Lastly, the functional importance of HIF-1 to the letrozole-
resistant cell phenotype was explored. In cancer cells,A) LTLTCa cells were plated in passage media and then treated with
and BCRP mRNA, and 18S rRNA were analyzed by real-time RT-PCR.
mpared with negative control after normalization to 18S rRNA (mean
7 for HIF-1α; P = 0.0026 for BCRP; one-way ANOVA). B) LTLTCa cells
for 48 hours. Total protein was extracted and HIF-1α and β-actin
overall densitometry results of n = 6 independent cell samples/group.
pared to negative control after normalization to β-actin (mean ± SD,
01, one-way ANOVA). ANOVA, analysis of variance; BCRP, breast cancer
standard deviation.
Figure 8 Protein expression in HER2+ cells and exemestane-resistant cells. A) MCF-7Ca (M), Hc7 and LTLTCa (LT) cells were plated in their
respective passage media. Total protein was extracted and HER2, phosphorylated- and total-ERK, ERα, HIF-1α, BCRP and β-actin protein were
analyzed by Western blot. Shown are representative blots and overall densitometry results of n = 6 independent cell samples/group. Densitometry
results are expressed as mean fold-change compared to MCF-7Ca after normalization to ERK (mean ± SD of n = 6 independent cell samples/group;
*versus MCF-7Ca, P <0.05; † versus MCF-7Ca, P <0.001, one-way ANOVA). Dashed lines indicate omitted lane in between M and Hc7 of the same
blots. B) AC1 (AC1) and AC1-ExR (ExR) cells were plated in their respective passage media. Total protein was extracted and HER2, phosphorylated-
and total-ERK, ERα, HIF-1α and β-actin protein were analyzed by Western blot. Shown are representative blots and overall densitometry results of
n = 6 independent cell samples/group. Densitometry results are expressed as mean fold-change compared to vehicle-treated cells after
normalization to β-actin (mean ± SD of n = 6 independent cell samples/group; *versus vehicle, P <0.0001, two-sided t-test). C) MCF-7/HER2 cells
were treated with either vehicle (V), 1 μM lapatinib (Lap), 100 nM ICI 182,780 (ICI) or 1 μM lapatinib + 100 nM ICI 182,780 (Lap + ICI) for 24 hours.
Total protein was extracted and HER2, phospho- and total-ERK1/2, ERα, HIF-1α and β-actin were analyzed by Western blot. Shown are representative
blots and overall densitometry results of n = 6 independent cell samples/group. Densitometry results are expressed as mean fold-change compared to
vehicle-treated cells after normalization to β-actin (mean ± SD of n = 6 independent cell samples/group; *versus vehicle, P <0.0001, one-way ANOVA).
ANOVA, analysis of variance; BCRP, breast cancer resistant protein; ERα, estrogen receptor alpha; HER2, human epidermal growth factor receptor 2;
HIF-1α, hypoxia inducible factor 1 α subunit; n, number; SD, standard deviation.
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http://breast-cancer-research.com/content/16/1/R15hypoxia and HIF-1 are known to be involved in increased
cell survival, chemoresistance [56,57], resistance to apop-
tosis [58] and maintenance of cancer stem cell characteris-
tics [59,60]. Previous findings from our laboratory [52] have
already demonstrated that letrozole resistance and cancer
stem cell characteristics of LTLTCa cells are reduced by in-
hibition of HER2 and/or BCRP. Although Gilani et al. did
not specifically test for the involvement of HIF-1, results of
this study combined with those of our current study dem-
onstrating the HER2-HIF-1-BCRP pathway, supports a role
for HIF-1 in determining the letrozole-resistant cell
phenotype.
To determine the functional significance of HIF-1 in
LTLTCa cells, the effect of specific inhibition of HIF-1α
expression by siRNA on mammosphere formation and
cell viability was analyzed (Figure 9). Consistent with our
previous study [52], LTLTCa cells formed mammospheres
(306 mammospheres/20,000 cells ± 5) (Figure 9B), and this
was decreased by BCRP siRNA treatment (64 mammo-
spheres/20,000 cells ± 9; P <0.001, one-way ANOVA). HIF-1α siRNA treatment similarly decreased mammosphere
formation in LTLTCa cells (101 mammospheres/20,000
cells ± 18), while CoCl2 increased formation (500 mammo-
spheres/20,000 cells ± 20) compared to negative control-
treated siRNA (P <0.001, one-way ANOVA). These results
correlated with the effect of HIF-1α inhibition on other
genes. HIF-1α siRNA treatment decreased BCRP mRNA
(P = 0.0377, one-way ANOVA), as well as expression of
GAPDH [61] (P = 0.0058, one-way ANOVA), another
known HIF-1 target gene, and BMI-1 (P = 0.0214, one-way
ANOVA), another stem cell marker [62] (Figure 9A). HIF-
1α siRNA treatment also significantly decreased LTLTCa
cell viability (P <0.0001, one-way ANOVA) in the presence
of increasing concentrations of letrozole (Figure 9C).
Effect of HIF-1α upregulation on MCF-7Ca cells
To further confirm the physiological role of HIF-1 and
BCRP, converse experiments were done to investigate
whether MCF-7Ca cells could become more letrozole-
resistant with increased HIF-1α. CoCl2 was used to
Figure 9 Effect of HIF-1α and/or BCRP siRNA on mammosphere formation and cell proliferation in LTLTCa cells. A) LTLTCa cells were
treated with either negative control siRNA or HIF-1α siRNA for 48 hours. Total mRNA was extracted and HIF-1α, BCRP, GAPDH, Nanog, BMI-1 and
TWIST mRNA, and 18S rRNA were analyzed by real-time RT-PCR. Real-time results are expressed as the fold-change in mRNA levels compared with
negative control after normalization to 18S rRNA (mean ± SD, n = 6 independent cell samples/group; *versus vehicle; P = 0.0.132 HIF-1; P = 0.0058
GAPDH, P = 0.0377 BCRP, P = 0.0612 TWIST, P = 0.058 Nanog, P = 0.0214 BMI-1; two-sided t-test). B) LTLTCa cells were plated in passage media and
then treated with negative control siRNA, HIF-1α siRNA, BCRP siRNA, or 100 μM CoCl2 for 48 hours. Cells were then collected and resuspended in
mammosphere media on low-attachment cell culture wells. Results are expressed as number of mammospheres counted per 20,000 cells plated
(mean ± SD, n = 6 independent cell samples/group; *versus negative control, P <0.001; † versus CoCl2, P < 0.001; overall P <0.0001, one-way
ANOVA). BCRP siRNA confirmed to decrease BCRP expression (0.35- and 0.15-fold versus negative control, P <0.01, one-way ANOVA; data not shown).
C) Viability of the cells was measured by the MTT assay after 48 hours treatment with negative control or HIF-1 alpha siRNA and subsequently 6 day
treatment with increasing doses of letrozole. Results are expressed as percent of 0 μM letrozole (vehicle) (mean ± SD, n = 4 independent cell samples/
group; *versus 0 μM letrozole, P <0.001; overall P <0.0001 one way ANOVA). ANOVA, analysis of variance; BCRP, breast cancer resistant protein; HIF-1α,
hypoxia inducible factor 1 α subunit; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide; n, number; SD, standard deviation.
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http://breast-cancer-research.com/content/16/1/R15increase HIF-1α expression in MCF-7Ca cells and the ef-
ficacy of CoCl2 was confirmed by Western blot analysis
and RT-PCR. Within 24 hours of CoCl2 treatment, HIF-
1α protein and BCRP mRNA and protein expression
were increased in MCF-7Ca cells (Figure 10A-B). Cell
viability experiments in the presence of increasing con-
centrations of letrozole were then performed (P <0.0001,
one-way ANOVA). Consistent with previous findings
from our laboratory [12], MCF-7Ca cells not treated with
CoCl2 were sensitive to the growth inhibitory effects of
letrozole (Figure 10C). Additional treatment of MCF-7Ca
cells with CoCl2 significantly increased their resistance to
letrozole. The effects of CoCl2 were attributable to HIF-1,
as co-treatment of MCF-7Ca cells with CoCl2 and HIF-1α
siRNA returned their sensitivity to letrozole. Overall, the
physiological experiments on LTLTCa and MCF-7Ca cellsindicate that HIF-1 is likely involved in both cancer stem
cell characteristics and cell viability.
Discussion
Prior to this study, AI resistance was associated with in-
creased dependence on growth factors and decreased de-
pendence on ERα. However, the role that such molecular
changes play in AI resistance and the mechanism by which
they elicit their effects were not known. Novel results from
this study demonstrated that nonhypoxic expression of
HIF-1 mediates HER2’s effects on letrozole-resistance. Spe-
cifically, the HER2-activated PI3K/Akt pathway increases
HIF-1α protein synthesis in LTLTCa cells. HIF-1α, in turn,
upregulates expression of BCRP and other genes and con-
tributes to letrozole resistance and stem cell characteristics
of LTLTCa cells.
Figure 10 Effect of CoCl2 on MCF-7Ca protein expression and cell viability. A-B, MCF-7Ca cells were incubated in steroid-free media and
then treated with 100 μM CoCl2 for 0 to 24 hours. A) Total protein was extracted and HIF-1α, BCRP, and β-actin were analyzed by Western blot
analysis. Shown are representative blots and overall densitometry results of n = 6 independent cell samples/group. Densitometry results are
expressed as mean fold-change in protein levels compared to 0 hours after normalization to β-actin (mean ± SD of n = 4 independent cell
samples/group, *versus 0 hours; P = 0.0005 for HIF-1a; P = 0.0065 for BCRP, two-sided t-test). B) Total RNA was extracted and BCRP mRNA and 18S
rRNA were analyzed by real-time RT-PCR analysis. Results are expressed as the mean fold-change in mRNA levels compared with 0 hours after
normalization to 18S rRNA (mean ± SD, n = 4 independent cell samples/group; *versus 0 hours, P <0.001; overall P = 0.0002, one-way ANOVA).
C) Viability of cells was measured by MTT assay after five days of treatment with increasing doses of letrozole following 48 hours pre-treatment
with or without 100 μM CoCl2 and HIF-1α siRNA. Results are expressed as mean percent of 0 μM letrozole-without CoCl2-with negative control
siRNA (mean ± SD of n = 6 independent samples/group; *versus vehicle-negative control siRNA-0 μM letrozole, P <0.001; † versus vehicle-HIF-1α
siRNA and CoCl2-HIF-1α siRNA; effect of letrozole P <0.0001, effect of pre-treatment (vehicle/CoCl2 and negative control siRNA/HIF-1α siRNA)
P <0.0001, interaction between letrozole dose and pre-treatment P <0.0001; two-way ANOVA). ANOVA, analysis of variance; BCRP, breast cancer
resistant protein; HIF-1α, hypoxia inducible factor 1 α subunit; MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide; n, number;
SD, standard deviation.
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ity in LTLTCa cells is due to the HER2-activated PI3K/
Akt/mTOR pathway. This is consistent with findings by
others indicating hypoxia independent upregulation of
HIF-1α in cancer cells by loss of function of tumor sup-
pressor genes and gain of function of oncogenes [27]. The
oncogene HER2/neu, in particular, has been previously as-
sociated with nonhypoxic HIF-1 [24,25]. Laughner et al.
and Li et al. have demonstrated that transfection of HER2
into NIH/3 T3 cells or activation of HER2 in MCF-7 cells
led to activation of the PI3K/Akt pathway, and the subse-
quent increased HIF-1 expression via protein synthesis
and HIF-1 transcriptional activity. Previous studies have
also demonstrated the importance of mTOR [48,49]. In
addition, mTOR has been explored in two randomized tri-
als (BOLERO-2 and TAMRAD) as a potential therapeutic
target for overcoming endocrine therapy resistance [63].
Our current study provides evidence that this HER2-PI3K/Akt-mTOR-HIF-1 signaling mechanism can indeed
occur endogenously in HER2+ cells (Figures 3, 4, and 8),
leads to upregulation of BCRP (Figure 2), and has physio-
logical relevance as well as potential clinical implications
(for example, AI resistance; Figures 9 and 10).
Despite providing evidence that HER2 activation of the
PI3K/Akt-mTOR pathway regulates HIF-1α, this study
cannot completely exclude the involvement of ERα or the
MAPK pathway. In addition to overexpressing HER2,
LTLTCa cells also have decreased expression of ERα
(Figure 3). It is possible that ERα can also regulate non-
hypoxic HIF-1α expression in LTLTCa cells. Indeed, ERα-
and HIF-1-mediated signaling pathways are known to
interact antagonistically [18,19] and cooperatively [20-23].
Although this current study did not directly investigate
ERα’s role, the overexpression of HIF-1α observed in both
ERα + (Hc7 and Ac1-ExR) and ERα- (LTLTCa) HER2+
breast cancer cell lines, suggests that ERα status may not
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With regard to the MAPK pathway, inhibition of this path-
way did not affect HIF-1α expression in LTLTCa cells, but
it did decrease BCRP mRNA expression under basal, non-
hypoxic conditions. It is possible that the MAPK pathway is
involved in phosphorylation of HIF-1α rather than its syn-
thesis. Previous studies have shown that MAPK pathway-
mediated phosphorylation of HIF-1α occurs under non-
hypoxic conditions and can increase HIF-1α expression
and transcriptional activity [64,65]. These results could also
indicate the MAPK and PI3K/Akt pathways have very dis-
tinct functions in AI-resistant breast cancer cells, regulating
different subsets of genes. For example, the MAPK pathway
may be involved in HER2 regulation of genes that require
activation by phosphorylated ERαSer118. In contrast, the
PI3K/Akt pathway may be involved in HER2 regulation of
genes that require HIF-1.
Inherent upregulation of HIF-1α protein expression
under nonhypoxic conditions is another novel finding in
AI-resistant breast cancer. There is precedence for asso-
ciating HIF-1 expression with drug resistance in differ-
ent cancer cell types, including chronic myeloid
leukemia cells [66], gastric cancer cells [67], non-small
cell lung cancer cells [68], and even breast cancer cells
[58]. However, these previous cases involved hypoxia-
induced, HIF-1α rather than the non-hypoxic HIF-1.
Our findings are also consistent with previous clinical
evidence that HIF-1α is associated with letrozole resist-
ance. Generali et al. demonstrated that increased p-
MAPK and HIF-1α protein expression were significant
determinants of primary letrozole resistance in breast
cancer patients. In contrast, increased ERα andFigure 11 Proposed model of regulation and role of HIF-1α in AI residecreased p-MAPK were significant determinants of re-
sponse to letrozole treatment [56]. The protein expres-
sion patterns observed by Generali et al. are similar to
what is observed in letrozole-resistant LTLTCa and –
sensitive MCF-7Ca cells, respectively (Figures 3 and 6).
Although these clinical findings involve de novo letrozole
resistance, they still correlate with, and likely pertain to,
our laboratory’s results on acquired letrozole resistance.
These results combined suggest that HIF-1 is involved in
both de novo and acquired AI resistance and, therefore,
could be therapeutically targeted to prevent and treat re-
sistance to letrozole and the other AIs.
Lastly, this study indicates that HIF-1 may contribute
to letrozole resistance by mediating the effects of HER2
on target genes, such as BCRP. Previous findings by our
laboratory had implicated HER2 and BCRP in resistance
to the growth inhibitory effects of letrozole and to main-
tenance of stem cell characteristics in letrozole-resistant
breast cancer, and had demonstrated that its expression
was dependent on HER2 [35,52], but it was unclear until
now how HER2 regulated BCRP. Moreover, HIF-1 may
mediate the effects of HER2 on many other genes. Besides,
BCRP, other known HIF-1 target genes that may serve as
markers of letrozole resistance include: 1) cancer stem cell
maintenance markers (Oct-4, kit ligand, JARID1B); 2)
epithelial-mesenchymal-transition (EMT) markers (Snail,
vimentin); and 3) invasion markers (c-Met, endothelin 1,
fibronectin, MMP-2 and −4) [27,69]. Interestingly, another
known HIF-1 target gene,VEGF, was not upregulated in
LTLTCa cells compared to MCF-7Ca cells. It is possible
that nonhypoxic HIF-1 expression has different levels of
influence on different HIF-1 target genes, particularlystant breast cancer.
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factors. Indeed BCRP and VEGF both are known to be
regulated by additional transcription factors, such as
ERα [22,70].
Conclusions
Overall, this study provides novel evidence that non-
hypoxic HIF-1α is inherently expressed in AI-resistant
cells, upregulated by HER2-PI3K/Akt-mTOR pathway
and is an important factor in letrozole-resistant breast
cancer cells, regulating target genes such as BCRP and
regulating AI responsiveness and cancer stem cell char-
acteristic expression. Thus, HIF-1α could be used as a
diagnostic marker and/or therapeutic target. Based on
this, a proposed model of acquired AI-resistance may in-
volve the following scenario: under non-hypoxic condi-
tions, when the breast cancer cell population and tumor
size have been reduced by letrozole treatment and prior to
significant tumor hypoxia, a switch from ERα- to growth
factor (for example, HER2)-mediated signaling occurs via
PI3K/Akt and mTOR, which leads to increased HIF-1α
expression and activation of HIF-1 target genes (for ex-
ample, BCRP) that contribute to AI resistance (Figure 11).
Consequently, inhibition of HIF-1 expression and/or
activity would prolong cancer cell sensitivity to AIs and
prevent recurrence and metastasis. Indeed, a number of
anti-cancer drugs in clinical use are also known to inhibit
HIF-1 [27]. They include HER2 inhibitor, trastuzumab
[24] and lapatinib. Furthermore, as demonstrated in this
study that HIF-1 is regulated mainly via the PI3K/Akt/
mTOR pathway, inhibition of the downstream affecter of
this pathway using mTOR inhibitors, such as rapamycin,
temsirolimus/CCI-779 and everolimus/RAD-001, can also
be considered [24,71-73]. There is also EZN-2968, a spe-
cific HIF-1α mRNA inhibitor, shown to reduce cancer cell
viability and xenograft tumor growth, which is currently
under phase I clinical trial [74]. Any of these anti-cancer
drugs could now potentially, based on the evidence pro-
vided by this study, be applied to the prevention and treat-
ment of AI-resistant breast cancer.Additional file
Additional file 1: Table S1.1. Test results conducted to compare mean
differences of normalized, log-transformed HIF-1α mRNA expression at
various time points of actinomycin D for LTLTCa and MCF-7Ca cells.
Shown are estimated mean differences in log transformed, normalized
HIF-1α mRNA expression between different timepoints of actinomycin
D treatment. Table results are estimated mean differences in log trans-
formed, normalized HIF-1α mRNA expression between different timepoints
of actinomycin D treatment calculated from the same data as shown
Figure 1B data, which indicates trend over time. Pre-specified timepoints
compared within each cell line were 0 versus 2 hours, 2 versus 4 hours, or
4 versus 16 hours. Data were analyzed by linear mixed effect model
adjusting for experiment, cell line, and cell line*time interaction mRNA. Fixed
effects for time, experiment, cell lines and interactions between time andcell lines were determined (means ± SD of n = 6 independent samples/
group; P <0.001 for effect of cell line, time, their interaction and experiment).
NS, not significant, P >0.05. Table S1.2. Test results conducted to compare
mean differences of normalized, log-transformed BCRP mRNA expression at
various time points of actinomycin D for both LTLTCa and MCF-7Ca cells.
Table results are estimated mean differences in log transformed, normalized
BCRP mRNA expression between different timepoints of actinomycin
D treatment calculated from the same data as shown in Figure 2C. Pre-
specified timepoints compared within each cell line were 0 versus 2 hours,
2 versus 4 hours, or 4 versus 16 hours. Data were analyzed by linear mixed
effect model adjusting for experiment, cell line, and cell line*time interaction
mRNA. Fixed effects for time, experiment, cell lines and interactions
between time and cell lines were determined (means ± SD of n = 6
independent samples/group; P <0.001 for effect of time and cell line*time
interaction). NS, not significant, P >0.05.
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